SMS Pharmaceuticals Limited

BSE:532815 Stock Report

Market Cap: ₹19.6b

SMS Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

SMS Pharmaceuticals's earnings have been declining at an average annual rate of -4.9%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 9.6% per year. SMS Pharmaceuticals's return on equity is 10.5%, and it has net margins of 7.7%.

Key information

-4.9%

Earnings growth rate

-5.0%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate9.6%
Return on equity10.5%
Net Margin7.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How SMS Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:532815 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247,6855937160
30 Jun 247,3845706660
31 Mar 247,0934986580
31 Dec 236,1293616150
30 Sep 236,0022885980
30 Jun 235,9301505710
31 Mar 235,221-715480
31 Dec 224,335-425350
30 Sep 224,06095320
30 Jun 224,2112595170
31 Mar 225,1996225150
31 Dec 216,3487894990
30 Sep 216,6129114750
30 Jun 216,1727914420
31 Mar 215,6326254150
31 Dec 204,9114584050
30 Sep 204,2263193980
30 Jun 204,1303083860
31 Mar 204,1433164100
31 Dec 194,2063863980
30 Sep 194,4124053890
30 Jun 194,6064063660
31 Mar 194,6674003720
31 Mar 184,6393173430
31 Mar 174,3882852880
31 Mar 166,0324094060
31 Dec 155,9023915790
30 Sep 155,8283965660
30 Jun 155,6513433300
31 Mar 155,7933525330
31 Dec 145,7303585040
30 Sep 145,6243274930
30 Jun 145,5673262820
31 Mar 145,1802044550
31 Dec 133,9766863720

Quality Earnings: 532815 has high quality earnings.

Growing Profit Margin: 532815's current net profit margins (7.7%) are higher than last year (4.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 532815's earnings have declined by 4.9% per year over the past 5 years.

Accelerating Growth: 532815's earnings growth over the past year (106.2%) exceeds its 5-year average (-4.9% per year).

Earnings vs Industry: 532815 earnings growth over the past year (106.2%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: 532815's Return on Equity (10.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:36
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SMS Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anil BurraFirstCall Research